The risk of immunization IgG following Rh immune globulin therapy.
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000918:Antibody Specificity; D001789:Blood Group Antigens; D001787:Blood Group Incompatibility; D003298:Coombs Test; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007109:Immunity; D007074:Immunoglobulin G; D007136:Immunoglobulins; D010641:Phenotype; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System; D012217:Rheumatoid Factor / Q000032:analysis; D005719:gamma-Globulins / Q000009:adverse effects* / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D001789:Blood Group Antigens; D007074:Immunoglobulin G; D007136:Immunoglobulins; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins; D012217:Rheumatoid Factor